Alzheimer's disease (AD) is pathologically defined by the presence of fibrillar amyloid β (Aβ)
peptide in extracellular senile plaques and tau filaments in intracellular neurofibrillary …

The quantity of high-density lipoproteins (HDL) is represented as the serum HDL-C
concentration (mg/dL), while the HDL quality manifests as the diverse features of protein and …

The ɛ4 allele of apolipoprotein E (APOE) is the major genetic risk factor for Alzheimer's
disease (AD). Although there have been numerous studies attempting to elucidate the …

Progressive cerebral deposition of the amyloid β-protein (Aβ) in brain regions serving
memory and cognition is an invariant and defining feature of Alzheimer disease. A highly …

Protein and peptides are converted from their soluble forms into highly ordered fibrillar
aggregates under various conditions inside the cell. Such transitions confer diverse …

Alzheimer's disease (AD) is an incurable and fatal progressive neurodegenerative disorder
associated with memory and cognition impairment. AD is one of the top medical care …

Alzheimer′ s disease (AD) is the most common form of dementia in the elderly. Memory
loss in AD is increasingly attributed to soluble oligomers of the amyloid‐β peptide (AβOs) …

Alzheimer's disease (AD) constitutes a major public-health issue of our time. Regrettably,
despite our considerable understanding of the pathophysiological aspects of this disease …

To date there is no effective therapy for Alzheimer disease (AD). High levels of circulating
high density lipoprotein (HDL) and its main protein, apolipoprotein AI (apoA-I), reduce the …

Background Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied
during the 'preclinical'stage (pathology present with cognition intact) before severe neuronal …